Abstract: An interface structure for a biological environment including at least one composite electrical impulse generating layer comprising a matrix phase of a piezo polymer material, a first dispersed phase of piezo nanocrystals, and second dispersed phase of carbon nanotubes, the first and second dispersed phase presented through the matrix phase. The piezo polymer material and piezo nanocrystal convert mechanical motion into electrical impulses and accept electrons to charge the composite impulse generating layer. The carbon nanotubes provide pathways for distribution of the electrical impulses to a surface of the composite impulse generating layer contacting the biological environment. The carbon nanotubes further provide for the delivery of the byproducts of the free radical degradation from the biological environment to both piezo-nanocrystals and piezo-polymer.

Abstract: A photovoltaic unit that includes a biological interface for sensing an electrical signal from the biological tissue, the biological interface including a multilayered piezoelectric amplifier including a composite impulse generating layer including a matrix of a piezo polymeric material and dispersed phases including piezo nanocrystals and carbon nanotubes. The photovoltaic unit also includes a transducer structure comprising a fiber substrate having quantum dots present on a receiving end of the fiber. The receiving end of the fiber receiving the electrical signal. The quantum dots converts the electrical signal to a light signal.

Abstract: A multilayered structure that includes a light receiving section including at least one layer including a noble metal composition and a metal oxide composition, the light transducing section transducing the energy of photons received to the energy of electrons. The structure further includes a piezo composite amplifier layer comprising a piezo polymer matrix, a first dispersed phase of piezo nanoparticles and a second dispersed phase of carbon nanotubes. The piezo composite amplifier amplifying a signal from the energy of the electrons received from the light receiving section using piezo-electric effects. The nanostructure further includes an environmental interface layer for delivering the amplified signal received from the piezo composite amplifier layer to a biological environment.

Abstract: An interface structure for a biological environment including at least one composite electrical impulse generating layer comprising a matrix phase of a piezo polymer material, a first dispersed phase of piezo nanocrystals, and second dispersed phase of carbon nanotubes, the first and second dispersed phase presented through the matrix phase. The piezo polymer material and piezo nanocrystal convert mechanical motion into electrical impulses and accept electrons to charge the composite impulse generating layer. The carbon nanotubes provide pathways for distribution of the electrical impulses to a surface of the composite impulse generating layer contacting the biological environment. The carbon nanotubes further provide for the delivery of the byproducts of the free radical degradation from the biological environment to both piezo-nanocrystals and piezo-polymer.

Abstract: A photovoltaic unit that includes a biological interface for sensing an electrical signal from the biological tissue, the biological interface including a multilayered piezoelectric amplifier including a composite impulse generating layer including a matrix of a piezo polymeric material and dispersed phases including piezo nanocrystals and carbon nanotubes. The photovoltaic unit also includes a transducer structure comprising a fiber substrate having quantum dots present on a receiving end of the fiber. The receiving end of the fiber receiving the electrical signal. The quantum dots converts the electrical signal to a light signal.

Abstract: An interface structure for a biological environment including at least one composite electrical impulse generating layer comprising a matrix phase of a piezo polymer material, a first dispersed phase of piezo nanocrystals, and second dispersed phase of carbon nanotubes, the first and second dispersed phase presented through the matrix phase. The piezo polymer material and piezo nanocrystal convert mechanical motion into electrical impulses and accept electrons to charge the composite impulse generating layer. The carbon nanotubes provide pathways for distribution of the electrical impulses to a surface of the composite impulse generating layer contacting the biological environment. The carbon nanotubes further provide for the delivery of the byproducts of the free radical degradation from the biological environment to both piezo-nanocrystals and piezo-polymer.

Abstract: A multilayered structure that includes a light receiving section including at least one layer including a noble metal composition and a metal oxide composition, the light transducing section transducing the energy of photons received to the energy of electrons. The structure further includes a piezo composite amplifier layer comprising a piezo polymer matrix, a first dispersed phase of piezo nanoparticles and a second dispersed phase of carbon nanotubes. The piezo composite amplifier amplifying a signal from the energy of the electrons received from the light receiving section using piezo-electric effects. The nanostructure further includes an environmental interface layer for delivering the amplified signal received from the piezo composite amplifier layer to a biological environment.

Abstract: An interface structure for a biological environment including at least one composite electrical impulse generating layer comprising a matrix phase of a piezo polymer material, a first dispersed phase of piezo nanocrystals, and second dispersed phase of carbon nanotubes, the first and second dispersed phase presented through the matrix phase. The piezo polymer material and piezo nanocrystal convert mechanical motion into electrical impulses and accept electrons to charge the composite impulse generating layer. The carbon nanotubes provide pathways for distribution of the electrical impulses to a surface of the composite impulse generating layer contacting the biological environment. The carbon nanotubes further provide for the delivery of the byproducts of the free radical degradation from the biological environment to both piezo-nanocrystals and piezo-polymer.

Abstract: Therapeutic agents which target heat shock protein (hsp) 27 in vivo are used to provide treatment to individuals, particularly human individuals, suffering from prostate cancer and other cancers that overexpress hsp27. A therapeutic agent, for example an antisense oligonucleotide or RNAi nucleotide inhibitor with sequence specificity for hsp27 mRNA, for example human hsp27 mRNA, is administered to an individual suffering from prostate cancer or some other cancer expressing elevated levels of hsp 27 in a therapeutically effective amount. The therapeutic agent is suitably formulated into a pharmaceutical composition which includes a pharmaceutically acceptable carrier, and packaged in dosage unit form. A preferred dosage unit form is an injectable dosage unit form.

Abstract: Therapeutic agents which target heat shock protein (hsp) 27 in vivo are used to provide treatment to individuals, particularly human individuals, suffering from prostate cancer and other cancers that overexpress hsp27. A therapeutic agent, for example an antisense oligonucleotide or RNAi nucleotide inhibitor with sequence specificity for hsp27 mRNA, for example human hsp27 mRNA, is administered to an individual suffering from prostate cancer or some other cancer expressing elevated levels of hsp 27 in a therapeutically effective amount. The therapeutic agent is suitably formulated into a pharmaceutical composition which includes a pharmaceutically acceptable carrier, and packaged in dosage unit form. A preferred dosage unit form is an injectable dosage unit form.

Abstract: RNAi sequences that are useful as therapeutics in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease. These sequences target clusterin, IGFBP-5, IGFBP-2, both IGFBP-2 and -5 simultaneously, Mitf, and B-raf. The invention further provides for the use of these RNAi sequences in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease, and a method of treating such conditions through the administration of the RNA molecules with RNAi activity to an individual, including a human individual in need of such treatment.

Abstract: Therapeutic agents which target heat shock protein (hsp) 27 in vivo are used to provide treatment to individuals, particularly human individuals, suffering from prostate cancer and other cancers that overexpress hsp27. A therapeutic agent, for example an antisense oligonucleotide or RNAi nucleotide inhibitor with sequence specificity for hsp27 mRNA, for example human hsp27 mRNA, is administered to an individual suffering from prostate cancer or some other cancer expressing elevated levels of hsp 27 in a therapeutically effective amount. The therapeutic agent is suitably formulated into a pharmaceutical composition which includes a pharmaceutically acceptable carrier, and packaged in dosage unit form. A preferred dosage unit form is an injectable dosage unit form.

Abstract: Bispecific antisense oligonucleotides which consist essentially of a sequence of bases that is complementary to portions of both the gene encoding human IGFBP-2 and the gene encoding human IGFBP-5 are useful in as antisense therapeutics in the treatment of endocrine-regulated cancers.

Abstract: Therapeutic agents which target heat shock protein (hsp) 27 in vivo are used to provide treatment to individuals, particularly human individuals, suffering from prostate cancer and other cancers that overexpress hsp27. A therapeutic agent, for example an antisense oligonucleotide or RNAi nucleotide inhibitor with sequence specificity for hsp27 mRNA, for example human hsp27 mRNA, is administered to an individual suffering from prostate cancer or some other cancer expressing elevated levels of hsp 27 in a therapeutically effective amount. The therapeutic agent is suitably formulated into a pharmaceutical composition which includes a pharmaceutically acceptable carrier, and packaged in dosage unit form. A preferred dosage unit form is an injectable dosage unit form.

Abstract: Bispecific antisense oligonucleotides which consist essentially of a sequence of bases that is complementary to portions of both the gene encoding human IGFBP-2 and the gene encoding human IGFBP-5 are useful in as antisense therapeutics in the treatment of endocrine-regulated cancers.

Abstract: Therapeutic agents which target heat shock protein (hsp) 27 in vivo are used to provide treatment to individuals, particularly human individuals, suffering from prostate cancer and other cancers that overexpress hsp27. A therapeutic agent, for example an antisense oligonucleotide or RNAi nucleotide inhibitor with sequence specificity for hsp27 mRNA, for example human hsp27 mRNA, is administered to an individual suffering from prostate cancer or some other cancer expressing elevated levels of hsp 27 in a therapeutically effective amount. The therapeutic agent is suitably formulated into a pharmaceutical composition which includes a pharmaceutically acceptable carrier, and packaged in dosage unit form. A preferred dosage unit form is an injectable dosage unit form.

Abstract: Therapeutic agents which target heat shock protein (hsp) 27 in vivo are used to provide treatment to individuals, particularly human individuals, suffering from prostate cancer and other cancers that overexpress hsp27. A therapeutic agent, for example an antisense oligonucleotide or RNAi nucleotide inhibitor with sequence specificity for hsp27 mRNA, for example human hsp27 mRNA, is administered to an individual suffering from prostate cancer or some other cancer expressing elevated levels of hsp 27 in a therapeutically effective amount. The therapeutic agent is suitably formulated into a pharmaceutical composition which includes a pharmaceutically acceptable carrier, and packaged in dosage unit form. A preferred dosage unit form is an injectable dosage unit form.

Abstract: Therapeutic agents which target heat shock protein (hsp) 27 in vivo are used to provide treatment to individuals, particularly human individuals, suffering from prostate cancer and other cancers that overexpress hsp27. A therapeutic agent, for example an antisense oligonucleotide or RNAi nucleotide inhibitor with sequence specificity for hsp27 mRNA, for example human hsp27 mRNA, is administered to an individual suffering from prostate cancer or some other cancer expressing elevated levels of hsp 27 in a therapeutically effective amount. The therapeutic agent is suitably formulated into a pharmaceutical composition which includes a pharmaceutically acceptable carrier, and packaged in dosage unit form. A preferred dosage unit form is an injectable dosage unit form.

Abstract: RNAi sequences that are useful as therapeutics in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease. These sequences target clusterin, IGFBP-5, IGFBP-2, both IGFBP-2 and -5 simultaneously, Mitf, and B-raf. The invention further provides for the use of these RNAi sequences in the treatment of cancers of various types, including prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and melanoma; and Alzheimer's disease, and a method of treating such conditions through the administration of the RNA molecules with RNAi activity to an individual, including a human individual in need of such treatment.

Abstract: Therapeutic agents which target heat shock protein (hsp) 27 in vivo are used to provide treatment to individuals, particularly human individuals, suffering from prostate cancer and other cancers that overexpress hsp27. A therapeutic agent, for example an antisense oligonucleotide or RNAi nucleotide inhibitor with sequence specificity for hsp27 mRNA, for example human hsp27 mRNA, is administered to an individual suffering from prostate cancer or some other cancer expressing elevated levels of hsp27 in a therapeutically effective amount. The therapeutic agent is suitably formulated into a pharmaceutical composition which includes a pharmaceutically acceptable carrier, and packaged in dosage unit form. A preferred dosage unit form is an injectable dosage unit form.